Skip to Main Content

Advertisement intended for health care professionals

Skip Nav Destination

Azacitidine Approved for Juvenile Myelomonocytic Leukemia

August 30, 2022

September 2022

Azacitidine received U.S. Food and Drug Admin­istration approval for the treatment of newly diagnosed juvenile myelomonocytic leukemia. Approval was granted based on the results of the AZA-JMML-001 study.

The international, multicenter, open-label trial included 18 pediatric patients. Researchers sought to assess the safety, pharmacodynamics, pharmacokinetics, and activity of the drug before hematopoietic cell transplant.

Half of the patients had confirmed clinical responses at three months; three had a complete clinical remission and six had a partial clinical remission. Rash, upper respiratory tract infection, pyrexia, and anemia occurred in more than 30% of patients and were the most common adverse events.

Source: U.S. Food & Drug Administration, June 3, 2022.

Advertisement intended for health care professionals

Connect with us:

CURRENT ISSUE
November 2024

Advertisement intended for health care professionals

Close Modal

or Create an Account

Close Modal
Close Modal

Advertisement intended for health care professionals